|
|
|
|
|
|
Sponsored by: |
University of Michigan Cancer Center |
Information provided by: | University of Michigan Cancer Center |
ClinicalTrials.gov Identifier: | NCT00156286 |
This study involves being treated initially with a combination of drugs called irinotecan and cisplatin (induction therapy), followed by treatment with a drug called Gleevec (maintenance therapy). The main purpose of this study is to determine if this type of treatment will delay the growth of the tumor and if so, for how long. The investigators also want to find out how the tumor is affected solely by induction therapy with irinotecan and cisplatin, what side-effects occur when Gleevec maintenance therapy is used, and if this treatment (induction followed by maintenance therapy) will improve the duration of survival
Condition | Intervention | Phase |
Small Cell Lung Cancer |
Drug: Gleevec |
Phase II |
MedlinePlus related topics: | Cancer Lung Cancer |
ChemIDplus related topics: | Cisplatin Irinotecan Irinotecan hydrochloride Imatinib Imatinib mesylate |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment |
Official Title: | Phase II Trial of Gleevec (Imatinib Mesylate, STI571) Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive, Extensive-Stage Small Cell Lung Cancer |
Estimated Enrollment: | 20 |
Study Start Date: | March 2002 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
5. Adequate organ function
6. Patients must sign informed consent that details the investigational nature of the study according to the institutional and federal guidelines.
Exclusion Criteria:
United States, Michigan | |||||
Univeristy of Michigan Cancer Center | |||||
Ann Arbor, Michigan, United States, 48109 |
University of Michigan Cancer Center |
Principal Investigator: | Gregory Kalemkerian, M.D. | University of Michigan Cancer Center |
Study ID Numbers: | UMCC 2001-066 |
First Received: | September 7, 2005 |
Last Updated: | March 22, 2006 |
ClinicalTrials.gov Identifier: | NCT00156286 |
Health Authority: | United States: Institutional Review Board |
|
|
|
|